AKYA (Akoya) רווחיות לפי רווח גולמי

Akoya Biosciences (AKYA) is transforming spatial biology by creating tools for precision tissue analysis and personalized therapy. Scaling IT solutions within the B2B segment is expanding the company's presence in diagnostics, while gross margin profitability has reached 57.30. This indicator's dynamics preclude buying the asset at its peak, reflecting real operational efficiency. A steady influx of clients and high dependency on consumables ensure the stability of the ecosystem.
פילוחי מדדים פיננסיים ומדדי שוק עבור akoyabio.com (AKYA)

Gross margin determines production efficiency by measuring the profit share after deducting direct costs of product creation. Investors utilize this ratio to assess operational capital density and the business's ability to scale profitability without a proportional increase in expenses. The adjusted gross margin trend confirms the high added value of Akoya Biosciences (AKYA) PhenoCycler precision platforms within the spatial biology sector.